SAN FRANCISCO, Jan. 7 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that Vijay Samant, President and Chief Executive Officer, will participate in a panel discussion on biodefense and pandemic influenza Wednesday evening at the 26th Annual JPMorgan Healthcare Conference (San Francisco, CA - January 7-10).
The session is co-hosted by JP Morgan and McKenna, Long & Aldridge LLP. Co-keynotes for the session are Rajeev Venkayya, M.D., Former Special Assistant to the President and Senior Director for Biodefense at the White House Homeland Security Council, and Brian Kamoie, Deputy Assistant Secretary and Director, Office of Policy, Strategic Planning & Communications, Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services. Leading the subsequent roundtable discussion will be Ipsita Smolinski, Healthcare Policy Analyst and Vice President, JP Morgan Investment Research, and John Clerici, Partner, Government Contracts Practice and Government Affairs Group, and Co-chair, Public Health Practice, McKenna, Long & Aldridge LLP.
Vical researches and develops biopharmaceutical products based on its
patented DNA delivery technologies for the prevention and treatment of
serious or life-threatening diseases. Potential applications of the
company's DNA delivery technology include DNA vaccines for infectious
diseases or cancer, in which the expressed protein is an immunogen; cancer
immunotherapeutics, in which the expressed protein is an immune system
stimulant; and cardiovascular therapies, in which the expressed protein is
an angiogenic growth factor. The company is developing certain infectious
disease vaccines and cancer therapeutics intern
|SOURCE Vical Incorporated|
Copyright©2008 PR Newswire.
All rights reserved